96 related articles for article (PubMed ID: 27638721)
21. IDH1 mutation analysis in low cellularity specimen: a limitation of diagnostic accuracy and a proposal for the diagnostic procedure.
Choi J; Lee EY; Shin KJ; Minn YK; Kim J; Kim SH
Pathol Res Pract; 2013 May; 209(5):284-90. PubMed ID: 23561624
[TBL] [Abstract][Full Text] [Related]
22. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
23. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
Nobusawa S; Watanabe T; Kleihues P; Ohgaki H
Clin Cancer Res; 2009 Oct; 15(19):6002-7. PubMed ID: 19755387
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.
Joseph NM; Phillips J; Dahiya S; M Felicella M; Tihan T; Brat DJ; Perry A
Mod Pathol; 2013 Mar; 26(3):315-26. PubMed ID: 23041832
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma.
Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M
Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804
[TBL] [Abstract][Full Text] [Related]
26. Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples.
Avsar T; Sursal A; Turan G; Yigit BN; Altunsu D; Cantasir K; Duyu G; Bayoumi AB; Yapicier O; Acar M; Kilic T
Mol Diagn Ther; 2020 Jun; 24(3):327-338. PubMed ID: 32274701
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological significance and diagnostic accuracy of HER2 immunohistochemistry in colorectal cancer: a meta-analysis.
Pyo JS; Kang G; Park K
Int J Biol Markers; 2016 Dec; 31(4):e389-e394. PubMed ID: 27102863
[TBL] [Abstract][Full Text] [Related]
28. Assessment of the Association between Isocitrate Dehydrogenase 1 Mutation and Mortality Risk of Glioblastoma Patients.
Dai Y; Ning X; Han G; Li W
Mol Neurobiol; 2016 Apr; 53(3):1501-1508. PubMed ID: 25650121
[TBL] [Abstract][Full Text] [Related]
29. [A clinical and molecular study of long-term survival glioblastomas].
Wang X; Liu YH; Xie F; You C; Mao Q
Zhonghua Wai Ke Za Zhi; 2013 Feb; 51(2):166-70. PubMed ID: 23711013
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical demonstration of isocitrate dehydrogenase 1 (IDH1) mutation in a small subset of prostatic carcinomas.
Mauzo SH; Lee M; Petros J; Hunter S; Chang CM; Shu HK; Bellail AC; Hao C; Cohen C
Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):284-7. PubMed ID: 23235339
[TBL] [Abstract][Full Text] [Related]
32. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.
Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J
Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018
[TBL] [Abstract][Full Text] [Related]
33. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Agnihotri S; Aldape KD; Zadeh G
Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
[TBL] [Abstract][Full Text] [Related]
34. IDH1 mutation of gliomas with long-term survival analysis.
Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
[TBL] [Abstract][Full Text] [Related]
35. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
36. [The expression of IDH1 (R132H) is positively correlated with cell proliferation and angiogenesis in glioma samples].
Shi J; Zhao Y; Yuan Y; Wang C; Xie Z; Gao X; Xiao L; Ye J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):360-3. PubMed ID: 26927556
[TBL] [Abstract][Full Text] [Related]
37. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN
Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
39. The definition of primary and secondary glioblastoma.
Ohgaki H; Kleihues P
Clin Cancer Res; 2013 Feb; 19(4):764-72. PubMed ID: 23209033
[TBL] [Abstract][Full Text] [Related]
40. Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations?
Sarmiento JM; Mukherjee D; Black KL; Fan X; Hu JL; Nuno MA; Patil CG
J Neurol Surg A Cent Eur Neurosurg; 2016 May; 77(3):195-200. PubMed ID: 26935296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]